The FDA is proposing amendments to its sterility testing requirements for biologics to give industry greater flexibility and encourage use of technologically up-to-date testing methods. The elimination of specific — in some cases, outdated — requirements in 21 CFR Parts 600, 610 and 680 would recognize current practices while allowing manufacturers to take advantage of modern sterility test methods, the FDA said.
Washington Drug Letter